Indication: For the treatment of hypertension and angina pectoris
Pharmacology: Metoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).
Mechanism Of Action: Like betaxolol and atenolol, metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.
Interactions:
DrugBank: Interactions for Metoprolol
Interactions for Metoprolol:
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking
agents. Patients treated with extended release metoprolol succinate plus a catecholamine depletor should therefore be
closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural
hypotension.
Chemical IUPAC Name: 1-[4-(2-methoxyethyl)phenoxy]-3-(1-methylethylamino)propan-2-ol
Chemical Formula: C15H25NO3
Half Life: 3-7 hours
Drug Type: Approved Drug
# Accession No: APRD00208
CAS Registry Number: 37350-58-6
Metoprolol News (When available)
AstraZeneca's Toprol XL Has Downside RiskJan 9, 2006 New Ratings 0956 GMT [Dow Jones] AstraZeneca's (AZN.ISE) patent ruling over Toprol XL presents downside risk ahead of positive FY results next month, says Deutsche Bank. ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 Reuters.uk, Reuters) - AstraZeneca (AZN.L: Quote, Profile, Research) faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 Reuters LONDON (Reuters) - AstraZeneca Plc faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a move that would hit ...
AstraZeneca drug patent in troubleJan 9, 2006 CNN/Money FDA may end protection for top selling heart treatment Toprol XL; could open door to generics. LONDON (Reuters) - AstraZeneca Plc ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 ABC News Jan 9, 2006 — LONDON (Reuters) - AstraZeneca Plc faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a move ...
UPDATE 1-Glaxo has new shortage of heart, diabetes drugsJan 11, 2006 Reuters The letter suggests that for heart failure patients, doctors should consider prescribing Toprol-XL, a top-selling heart failure drug made by AstraZeneca Plc ...
Advair may get a stronger warning labelJan 11, 2006 Daily Press, ...our medicines. I take Lipitor for cholesterol, Norvasc, Altace and Toprol-XL for high blood pressure and Actos for diabetes. My ...
Tonic for high drug costsJan 1, 2006 Indianapolis Star, ...$780, respectively. Among the drugs surveyed, only Toprol XL (50 mg) wound up costing consistently more under Medicare. Of course ...
In this pitch to seniors, Medicare's the brandJan 7, 2006 Boston Globe, AstraZeneca's drugs include Toprol XL, a blood pressure medication that is among the 10 best-selling drugs for seniors in the nation, and Nexium, a treatment ...
The People's PharmacyJan 1, 2006 Seattle Times, Q: My job was outsourced last year, and I lost my health coverage. I take Lipitor, Norvasc, Altace, Toprol-XL and Actos. My wife takes Fosamax and Aciphex. ...
AstraZeneca's Toprol XL Has Downside RiskJan 9, 2006 New Ratings 0956 GMT [Dow Jones] AstraZeneca's (AZN.ISE) patent ruling over Toprol XL presents downside risk ahead of positive FY results next month, says Deutsche Bank. ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 Reuters.uk, Reuters) - AstraZeneca (AZN.L: Quote, Profile, Research) faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 Reuters LONDON (Reuters) - AstraZeneca Plc faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a move that would hit ...
AstraZeneca drug patent in troubleJan 9, 2006 CNN/Money FDA may end protection for top selling heart treatment Toprol XL; could open door to generics. LONDON (Reuters) - AstraZeneca Plc ...
AstraZeneca heart drug patent seen in jeopardyJan 9, 2006 ABC News Jan 9, 2006 — LONDON (Reuters) - AstraZeneca Plc faces a significant risk of losing US patent protection on its top-selling heart drug Toprol XL, in a move ...
UPDATE 1-Glaxo has new shortage of heart, diabetes drugsJan 11, 2006 Reuters The letter suggests that for heart failure patients, doctors should consider prescribing Toprol-XL, a top-selling heart failure drug made by AstraZeneca Plc ...
Advair may get a stronger warning labelJan 11, 2006 Daily Press, ...our medicines. I take Lipitor for cholesterol, Norvasc, Altace and Toprol-XL for high blood pressure and Actos for diabetes. My ...
Some Medicare drug plans may save over CanadaDec 30, 2005 St. Louis Post-Dispatch, ...$780, respectively. Among the drugs surveyed, only Toprol XL (50 mg) wound up costing consistently more under Medicare. Of course ...
In this pitch to seniors, Medicare's the brandJan 7, 2006 Boston Globe, AstraZeneca's drugs include Toprol XL, a blood pressure medication that is among the 10 best-selling drugs for seniors in the nation, and Nexium, a treatment ...
Ages change for assistanceJan 6, 2006 Scottsboro Daily Sentinel, Senior Rx often helps facilitate savings for the purchase of drugs like Celebrex, Mobic, Toprol, Norvasc, Nexium, and Prevacaid. ...
The People's PharmacyJan 1, 2006 Seattle Times, Q: My job was outsourced last year, and I lost my health coverage. I take Lipitor, Norvasc, Altace, Toprol-XL and Actos. My wife takes Fosamax and Aciphex. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
